Risankizumab for the treatment of moderate‐to‐severe psoriasis: A multicenter, retrospective, 1 year real‐life study

Several new biologic agents targeting IL23/Th17 axis, such as risankizumab, have been developed for the treatment of psoriasis. The aim of the present study was to analyze the efficacy and safety of risankizumab in patients with moderate‐to‐severe psoriasis over a 52‐week period. A multicentric retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Caldarola, Giacomo, Zangrilli, Arianna, Bernardini, Nicoletta, Bavetta, Mauro, De Simone, Clara, Graceffa, Dario, Bonifati, Claudio, Faleri, Sara, Giordano, Domenico, Mariani, Marco, Micheli, Adriana, Moretta, Gaia, Pagnanelli, Gianluca, Panasiti, Vincenzo, Provini, Alessia, Richetta, Antonio, Peris, Ketty, Bianchi, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287038/
https://www.ncbi.nlm.nih.gov/pubmed/35385202
http://dx.doi.org/10.1111/dth.15489

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287038/
https://www.ncbi.nlm.nih.gov/pubmed/35385202
http://dx.doi.org/10.1111/dth.15489

Ejemplares similares